Nordanest (Articaine Hydrochloride, Epinephrine Bitartrate)

Articaine blocks voltage‑gated sodium channels on neuronal membranes, preventing the influx of sodium ions required for depolarization. This inhibition stops nerve impulse propagation, resulting in loss of sensation. Epinephrine causes local vasoconstriction, decreasing blood flow, which limits systemic absorption of articaine and extends its anesthetic effect.

The specific dose of Nordanest is determined by the prescribing clinician based on the procedure, patient age, weight, and medical history. The prescriber selects the appropriate volume and concentration to achieve effective anesthesia while adhering to recommended maximum limits for articaine and epinephrine.

Safety data for articaine and epinephrine during pregnancy and lactation are limited. Use is generally reserved for situations where the benefit to the mother outweighs potential risks to the fetus or infant, and it should be prescribed only after careful risk‑benefit assessment by a qualified health professional.

To place an order, submit an enquiry on the Nordanest product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold-chain requirements), and necessary import documentation.

Both articaine (in Nordanest) and lidocaine are amide‑type local anesthetics, but articaine has a thiophene ring that enhances lipid solubility, allowing faster onset and deeper penetration, especially in dense bone. Epinephrine in Nordanest also prolongs anesthesia. However, individual patient response and safety considerations guide the choice between the two agents.

Nordanest should be stored at ambient temperature, preferably below 25 °C, in its original sealed container. Protect the product from direct sunlight, moisture, and extreme temperature fluctuations. Do not freeze the solution, and keep it out of reach of children.

Nordanest is supplied as a solution for oromucosal administration. The clinician injects the appropriate volume into the mucosal tissue adjacent to the target tooth or surgical site using a standard dental syringe. Proper aseptic technique and aspiration before injection help minimize the risk of intravascular administration.

The most serious adverse events include allergic reactions such as anaphylaxis, cardiovascular toxicity like arrhythmias, hypertension, or tachycardia due to epinephrine absorption, and rare cases of methemoglobinemia. Prompt recognition and emergency management are essential if any of these symptoms occur.

Nordanest is contraindicated in patients with known hypersensitivity to articaine, other amide local anesthetics, or epinephrine. It should also be avoided in individuals with uncontrolled severe hypertension, certain cardiac arrhythmias, or those taking non‑selective MAO inhibitors. Clinicians must assess each patient’s medical history before prescribing.